ArticleHepatology international2026
Epidemiological characteristics in Shanghai and a prognostic nomogram for 90 day adverse outcomes in acute hepatitis E.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
BACKGROUND &
aimsHepatitis E virus (HEV) represents a leading cause of acute viral hepatitis in China, yet large-scale studies characterizing its dynamic epidemiology and enabling early prediction of adverse outcomes remain scarce.
methodsWe performed a retrospective cohort study comprising 816 patients hospitalized with acute HEV infection (2019-2024). Predictors were identified through multivariable logistic regression, with Firth's penalized likelihood method applied to address potential small-sample bias, and bootstrap resampling (BCa 95% CI) used to validate estimate robustness. A prognostic nomogram was developed and externally validated in a prospective multicenter cohort, with performance evaluated using AUC, calibration curves, and decision curve analysis.
resultsAmong 816 patients (69.6% male, median age 60 years), HEV infection exhibited a winter-spring seasonal pattern in Shanghai, China. The overall 90 day adverse outcome rate was 4.5% in the general population and 18.1% in cirrhotic patients (aOR = 4.37, 95% CI: 1.69-11.33; p = 0.002). No 90 day adverse outcomes occurred in pregnant patients or those with HIV/AIDS. Chronic liver disease (CLD) (OR = 2.65, 1.27-5.70; Firth p = 0.008), MELD score (OR = 1.25, 1.18-1.32; Firth p < 0.001), and neutrophil-to-lymphocyte ratio (NLR) (OR = 1.18, 1.09-1.27; Firth p < 0.001) were independently associated with 90 day adverse outcomes. The CLD-MELD-NLR nomogram achieved high accuracy in the general population (AUC = 0.94, 95% CI: 0.89-0.98), and the MELD-NLR nomogram also performed outstandingly in the CLD subgroup (AUC = 0.90, 95% CI: 0.84-0.96). Both models demonstrated good calibration and clinical utility.
conclusionsThe distinct seasonality and disease burden of HEV in Shanghai highlight the need for targeted local public health measures. The robustly validated CLD-MELD-NLR and MELD-NLR nomograms provide practical tools for early risk stratification and personalized management across diverse clinical settings.
Indexed as
Identifiers
41678121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.